

## CHANGE - CHANGE IN CORPORATE INFORMATION::DEREGISTRATION OF WHOLLY-OWNED SUBSIDIARY

### Issuer

#### Issuer/ Manager

VALUETRONICS HOLDINGS LIMITED

### Announcement Details

#### Announcement Title

Change - Change in Corporate Information

#### Date & Time of Broadcast

28-Apr-2021 19:04:42

#### Status

New

#### Announcement Sub Title

Deregistration of Wholly-Owned Subsidiary

#### Announcement Reference

SG210428OTHRWXJS

#### Submitted By (Co./ Ind. Name)

Tse Chong Hing

#### Designation

Chairman and Managing Director

#### Description (Please provide a detailed description of the event in the box below)

Please refer to the attached announcement on deregistration of wholly-owned subsidiary, Huizhou Daya Bay Honor Tone Diagnostic Equipment Limited.

### Place Of Incorporation

#### Existing

Bermuda

#### New

### Registered Address

	Existing	New
--	----------	-----

### Attachments

[VHL-Deregistration of Subsidiary-HT Diagnostic-20210428.pdf](#)

Total size =40K MB



**VALUETRONICS HOLDINGS LIMITED**

(Incorporated in Bermuda)  
(Co. Reg. No: 38813)

---

**DEREGISTRATION OF WHOLLY-OWNED SUBSIDIARY**

---

The Board of Directors (“Board”) of Valuetronics Holdings Limited (the “Company”, and together with its subsidiaries, the “Group”) wishes to announce that the Company’s wholly-owned subsidiary in the People’s Republic of China (“PRC”) known as Huizhou Daya Bay Honor Tone Diagnostic Equipment Limited (“HT Diagnostic”), has been deregistered.

Established in 2016 with a registered capital of HK\$2 million and paid-up capital of HK\$2 million, HT Diagnostic is wholly-owned by Value Match Company Limited, which is wholly-owned by Value Creation Enterprises Limited, a wholly-owned subsidiary of the Company.

HT Diagnostic was envisaged to be engaged in the manufacturing of Diagnostic Equipment and to explore opportunities in the medical equipment sector in the PRC, however, opportunities for the Company in medical equipment sector have not come into fruition. As such, the Company decided to deregister HT Diagnostic as part of an overall consolidation of its operations.

The deregistration of the HT Diagnostic is not expected to have any material impact on the net tangible assets per share or earnings per share of the Company for the financial year ending 31 March 2022.

None of the Directors or controlling shareholders of the Company has any interest, direct or indirect, in the above transaction, save for their shareholdings (if any) in the Company.

BY ORDER OF THE BOARD

Tse Chong Hing  
Chairman & Managing Director

28 April 2021